Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: A prognostic study within the CLARICOR trial

Immunobiology

Volumn 218, Issue 7, 2013, Pages 945-951

  Harutyunyan, Marina ^a   Gøtze, Jens P ^a   Winkel, Per ^a   Johansen, Julia S ^b   Hansen, Jørgen Fischer ^c   Jensen, Gorm Boje ^d   Hilden, Jørgen ^e   Kjøller, Erik ^b   Kolmos, Hans J ^f   Gluud, Christian ^a   Kastrup, Jens ^a  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Biomarker; Coronary artery disease; Hs CRP; Inflammation; Mortality; NT proBNP; YKL 40

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIGOXIN; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE PROTEIN; NITRATE; PROTEIN YKL 40; UNCLASSIFIED DRUG;

AGE; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENDER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SMOKING;

ADIPOKINES; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOTONIC AGENTS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LECTINS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84877128078     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.10.015     Document Type: Article

References (29)

1. Bisoendial R.J., Boekholdt S.M., Vergeer M., Stroes E.S., Kastelein J.J. C-reactive protein is a mediator of cardiovascular disease. Eur. Heart J. 2010, 31:2087-2091.
2. Bojesen S.E., Johansen J.S., Nordestgaard B.G. Plasma YKL-40 levels in healthy subjects from the general population. Clin. Chim. Acta 2011, 412:709-712.
3. Boot R.G., van Achterberg T.A., van Aken B.E., Renkema G.H., Jacobs M.J., Aerts J.M., de Vries C.J. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler. Thromb. Vasc. Biol. 1999, 19:687-694.
4. Chupp G.L., Lee C.G., Jarjour N., Shim Y.M., Holm C.T., He S., Dziura J.D., Reed J., Coyle A.J., Kiener P., Cullen M., Grandsaigne M., Dombret M.C., Aubier M., Pretolani M., Elias J.A. A chitinase-like protein in the lung and circulation of patients with severe asthma. N. Engl. J. Med. 2007, 357:2016-2027.
5. Corrado E., Rizzo M., Coppola G., Fattouch K., Novo G., Marturana I., Ferrara F., Novo S. An update on the role of markers of inflammation in atherosclerosis. J. Atheroscler. Thromb. 2010, 17:1-11.
6. Drakopoulou M., Toutouzas K., Stefanadi E., Tsiamis E., Tousoulis D., Stefanadis C. Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis 2009, 206:335-339.
7. Francescone R.A., Scully S., Faibish M., Taylor S.L., Oh D., Moral L., Yan W., Bentley B., Shao R. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J. Biol. Chem. 2011, 286:15332-15343.
8. Gluud C., ls-Nielsen B., Damgaard M., Fischer H.J., Hansen S., Helo O.H., Hildebrandt P., Hilden J., Jensen G.B., Kastrup J., Kolmos H.J., Kjoller E., Lind I., Nielsen H., Petersen L., Jespersen C.M. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 2008, 111:280-287.
9. Goetze J.P. ProBNP-derived peptides in cardiac disease. Scand. J. Clin. Lab. Invest. 2004, 64:497-510.
10. Harutyunyan M., Christiansen M., Johansen J.S., Kober L., Torp-Petersen C., Kastrup J. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 2011.
11. Harutyunyan M.J., Mathiasen A.B., Winkel P., Gotze J.P., Hansen J.F., Hildebrandt P., Jensen G.B., Hilden J., Jespersen C.M., Kjoller E., Kolmos H.J., Gluud C., Kastrup J. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial. Scand. J. Clin. Lab. Invest. 2011, 71:52-62.
12. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 1979, 65-70.
13. Jespersen C.M., ls-Nielsen B., Damgaard M., Hansen J.F., Hansen S., Helo O.H., Hildebrandt P., Hilden J., Jensen G.B., Kastrup J., Kolmos H.J., Kjoller E., Lind I., Nielsen H., Petersen L., Gluud C. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006, 332:22-27.
14. Johansen J.S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan. Med. Bull. 2006, 53:172-209.
15. Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?. Immunobiology 2012, 217:483-491.
16. Kastrup J., Johansen J.S., Winkel P., Hansen J.F., Hildebrandt P., Jensen G.B., Jespersen C.M., Kjoller E., Kolmos H.J., Lind I., Nielsen H., Gluud C. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur. Heart J. 2009, 30:1066-1072.
17. Kim H., Yang D.H., Park Y., Han J., Lee H., Kang H., Park H.S., Cho Y., Chae S.C., Jun J.E., Park W.H. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ. J. 2006, 70:1379-1384.
18. Kushner I., Feldmann G. Control of the acute phase response. Demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit. J. Exp. Med. 1978, 148:466-477.
19. Kzhyshkowska J., Gratchev A., Goerdt S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark. Insights 2007, 2:128-146.
20. Lee C.G., Da Silva C.A., la Cruz C.S., Ahangari F., Ma B., Kang M.J., He C.H., Takyar S., Elias J.A. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu. Rev. Physiol. 2011, 73:479-501.
21. Lee-Lewandrowski E., Januzzi J.L., Green S.M., Tannous B., Wu A.H., Smith A., Wong A., Murakami M.M., Kaczmarek J., Apple F.S., Miller W.L., Hartman K., Jaffe A.S. Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay. Clin. Chim. Acta 2007, 386:20-24.
22. Mathiasen A.B., Henningsen K.M., Harutyunyan M.J., Mygind N.D., Kastrup J. YKL-40: a new biomarker in cardiovascular disease?. Biomark. Med. 2010, 4:591-600.
23. Mygind N.D., Harutyunyan M.J., Mathiasen A.B., Ripa R.S., Thune J.J., Gotze J.P., Johansen J.S., Kastrup J. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm. Res. 2011, 60:281-287.
24. Nishikawa K.C., Millis A.J. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp. Cell Res. 2003, 287:79-87.
25. Rathcke C.N., Kistorp C., Raymond I., Hildebrandt P., Gustafsson F., Lip G.Y., Faber J., Vestergaard H. Plasma YKL-40 levels are elevated in patients with chronic heart failure. Scand. Cardiovasc. J. 2010, 44:92-99.
26. Rathcke C.N., Persson F., Tarnow L., Rossing P., Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 2009, 32:323-328.
27. Sabatine M.S., Morrow D.A., Jablonski K.A., Rice M.M., Warnica J.W., Domanski M.J., Hsia J., Gersh B.J., Rifai N., Ridker P.M., Pfeffer M.A., Braunwald E. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007, 115:1528-1536.
28. Wang Y., Ripa R.S., Johansen J.S., Gabrielsen A., Steinbruchel D.A., Friis T., Bindslev L., Haack-Sorensen M., Jorgensen E., Kastrup J. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand. Cardiovasc. J. 2008, 42:295-302.
29. Wood W.G., Ludemann J., Mitusch R., Heinrich J., Maass R., Frick U. Evaluation of a sensitive immunoluminometric assay for the determination of C-reactive protein (CRP) in serum and plasma and the establishment of reference ranges for different groups of subjects. Clin. Lab. 2000, 46:131-140.